• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EYEFI Expanding to the United States

    6/23/21 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email

    TORONTO, ON / ACCESSWIRE / June 23, 2021 / EYEFI Group Technologies Inc. (CSE:EGTI)(OTC:EGTTF) ("the "Company") is pleased to announce the appointment of Dr Ian Meredith AM to EYEFI's US based advisory board to assist with expansion activities in the United States. Dr Meredith is Executive Vice President and global Chief Medical Officer, at Boston Scientific Corporation (NYSE:BSX) (a US$60B Fortune 500 device company headquartered in the United States). In this role, he is responsible for leading clinical science and medical affairs across Boston Scientific and providing global leadership of the company's clinical trial strategy.

    EYEFI's geospatial technology ‘SPARC' is a registered patent in 7 countries including Canada and the United States. The technology includes a set of proprietary algorithms that can be installed on any camera or sensor and used to determine the location of any object being viewed or pointed at by the device. The solution does not use GPS, satellite or the internet and it is totally covert and undetectable when in use. The algorithms also have several proprietary modules, for instance an image that has been captured using SPARC can be shared or integrated into 3rd party applications to conduct a reverse look up on any pixel to pull location data, plus any other dataset on the internet that is relevant to that location at that time.

    There are a broad range of use cases for the SPARC technology for use in drones, autonomous vehicles, military, and in medical devices. There is a growing demand for medical devices to leverage spatial and 3D data, such as Google Glass (owned by Google), Tesla owned by Elon Musk, and NeuraLink; another company backed by Elon Musk that is developing devices to interface with the human brain.

    Dr Meredith has joined EYEFI's US based advisory board to assist the Company with strategic introductions to potential new US based customers and channel partners. Several key targets have already been identified in addition to those mentioned above.

    Dr Meredith's remuneration will include 20,000 options with an exercise price of $.82 with 12-month expiry. An additional 100,000 options will be issued with an exercise price of $1.30, with vesting conditions (remain as consultant and provide a minimum of 3 strategic referrals in the US) with 18-month expiry.

    Ian Meredith said:

    "I am delighted to join EYEFI's US advisory board to help drive/design/guide the expansion of this technology into the rapidly evolving healthcare milieu. As every step on the healthcare continuum continues its remarkable digital transformation in the 21st century, there may well be significant opportunities to integrate EYEFI's inspired technology into meaningful healthcare solutions. I am delighted to have the opportunity to help guide this translation."

    About EYEfi in detail:

    EYEfi is connecting the world's people and devices with the world around them, in real-time and in ways not previously possible.

    EYEfi is a software and electronics engineering company that has developed, patented and commercialized an innovative spatial technology; spatial, predictive, approximation and radial convolution (SPARC) and an associated product suite, that turns sensors, cameras and smartphones (fixed, mobile, airborne, portable or handheld) into geo-target co-ordinate acquisition devices.

    EYEfi has also developed IIoT sensor hardware and associated cloud software, as a second pillar within its product offering. EYEfi Cloud is a next generation cloud platform that provides a secure and centralized environment where customers can manage their EYEfi product deployments and applications.

    On behalf of the board of directors of
    EYEFI GROUP TECHNOLOGIES INC.

    "Simon Langdon"
    Simon Langdon, CEO

    For more information contact:

    Simon Langdon
    Chief Executive Officer
    EYEfi Group Technologies Inc.

    Mark van der Horst
    Investor Relations
    EYEfi Group Technologies Inc.
    Telephone: +1 (604) 760 7604
    Email: mark@galecapital.com

    THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

    FORWARD LOOKING INFORMATION

    This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information.

    The forward-looking statements are based on the reasonable assumptions, estimates, opinions and analyses of management made in light of its experience and perception of historical trends in the delivery of services through its Cloud, current conditions, expected future developments and other factors management of the Company believes are appropriate, relevant and reasonable in the circumstances at the date that such statements are made. All of these assumptions, estimates and opinions will necessarily be subject to change due to future events and other circumstances outside the control of the Company, including the effect of the Covid 19 virus. The Company has based the forward looking information on various material assumptions, including: despite the threat of the Covid 19 virus, the Company will sustain or increase profitability although on a slower projection then previously planned, and will be able to fund its operations with existing capital and projected revenue from its current agreements with its Channel Partners; the Company will be able to attract and retain key personnel in future if required; the general business, economic, financial market, regulatory and political conditions in which the Company operates will remain positive as its services can be provided in the Company's Cloud although deliver of its hardware may be affect by supply chain disruptions; that the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiary will remain constant and the Company will not become subject to any material legal proceedings; the economy generally; competition, and anticipated and unanticipated costs.

    Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors, assumptions and exclusions is not exhaustive.

    The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

    SOURCE: EYEFI Group Technologies Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/652789/EYEFI-Expanding-to-the-United-States

    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX

    DatePrice TargetRatingAnalyst
    5/29/2026Outperform → Peer Perform
    Wolfe Research
    5/28/2026$55.00Overweight → Equal Weight
    Wells Fargo
    3/30/2026$88.00Strong Buy → Outperform
    Raymond James
    10/3/2025Buy → Hold
    Erste Group
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    6/16/2025$118.00Outperform
    Leerink Partners
    4/16/2025$113.00Hold → Buy
    Needham
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $BSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

    Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well a

    5/19/26 6:31:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific enters into $2 billion accelerated share repurchase agreement

    MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, Boston Scientific will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52

    5/18/26 7:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces strategic investment in MiRus LLC

    Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloyMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has invested $1.5 billion in return for an approximately 34% equity stake in MiRus LLC, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. As part of the investment agreement, Boston Scientific also received an exclusive option to acqu

    5/18/26 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    SEC Filings

    View All

    SEC Form SD filed by Boston Scientific Corporation

    SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/21/26 4:16:28 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/18/26 7:17:15 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/18/26 7:15:03 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    6/1/26 4:18:00 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:10 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boston Scientific downgraded by Wolfe Research

    Wolfe Research downgraded Boston Scientific from Outperform to Peer Perform

    5/29/26 8:06:22 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Boston Scientific from Overweight to Equal Weight and set a new price target of $55.00

    5/28/26 8:45:02 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Raymond James with a new price target

    Raymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00

    3/30/26 8:15:23 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:10 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:20:09 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Leadership Updates

    Live Leadership Updates

    View All

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    4/3/25 11:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BSX
    Financials

    Live finance-specific insights

    View All

    Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

    MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Mike Mahoney, chairman and chief executive officer, and Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. Additionally, the company will webcast its conference call discussing financial results and business highlights for the second quarter end

    5/4/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces results for first quarter 2026

    MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion or $0.90 per share (EPS), compared to $674 million or $0.45 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.75 a year ago. "Our global

    4/22/26 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces conference call discussing first quarter 2026 results

    MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev

    3/30/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 11:49:03 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 8:35:54 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care